- Vanda-VTR-297-1101-A Phase I multicenter, open label, dose-escalation study to determine the maximum tolerated does for Trichostatin A in subjects with replapsed or refractory Hematologic Malignancies.
- Adagene Inc.-ADG106-A Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Hematologic Malignancies
April 12, 2019